PO.ET06.05 · 实验与分子治疗

CDX1与PVT1外显子9相关启动子结合驱动侵袭性前列腺癌中致癌性PVT1外显子9的过表达

CDX1 binding to the PVT1 exon 9-associated promoter drives oncogenic PVT1 exon 9 overexpression in aggressive prostate cancer

海报缩略图:CDX1与PVT1外显子9相关启动子结合驱动侵袭性前列腺癌中致癌性PVT1外显子9的过表达
编号 5730 展板 19 时间 4/21 02:00–05:00 区域 Section 13 主讲 Chinedum Udekwu, BS;MS
分会场 Molecular Targets 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Chinedum C. Udekwu1, Siti K. Nuraziza1, Seidu Adams1, Rachel E. Bonnaci1, E. Oluwabunmi Olapade-Olaopa2, Olorunseun O. Ogunwobi1

1Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI,2Department of Surgery, University of Ibadan, Ibadan, Nigeria

摘要 Abstract

中文摘要
本研究阐明了一条先前未表征的表观遗传-转录调控轴,该轴涉及转录因子CDX1和PVT1外显子9相关启动子(PEAP),在侵袭性前列腺癌中调控PVT1外显子9的过表达。位于8q24致癌基因座的长非编码RNA(lncRNA)PVT1已被证明参与前列腺肿瘤发生和进展;然而,其外显子特异性转录激活的分子机制仍不清楚。通过使用FIMO分析进行计算机基序发现,我们在PEAP序列内鉴定出一个高亲和力的CDX1共识结合位点,提示其潜在的转录调控作用。对前列腺癌患者配对肿瘤及相邻正常组织的DNA甲基化分析显示,PEAP启动子低甲基化,同时伴随PVT1外显子9的显著上调。在PVT1外显子9过表达的细胞(MDA-PCa-2b和C22OH)中,siRNA介导的CDX1沉默减弱了PVT1外显子9的表达,而在RWPE-1细胞中过表达CDX1则增强了PVT1外显子9的转录。免疫组化和免疫荧光分析证实CDX1在高Gleason分级肿瘤中的核定位和表达升高,凸显了其作为转录激活因子的作用。使用数字PCR,在MDA-PCa-2b和C22OH中通过CRISPR介导的碱基编辑对PEAP上的CDX1结合序列进行编辑,结果显示与对照相比PVT1外显子9拷贝数大幅减少。总的来说,这些发现勾勒出一条依赖于CDX1与PEAP结合的CDX1-PEAP-PVT1信号轴,从而驱动致癌性PVT1外显子9的过表达。这一机制性见解为理解PVT1外显子特异性调控提供了新框架,并将CDX1-PEAP相互作用确定为PVT1外显子9过表达前列腺癌治疗干预的一个有前景的分子靶点。
查看英文原文 English abstract
This study elucidates a previously uncharacterized epigenetic-transcriptional regulatory axis involving the transcription factor CDX1 and the PVT1 exon 9-associated promoter (PEAP) that governs PVT1 exon 9 overexpression in aggressive prostate cancer. The long noncoding RNA ( lncRNA ) PVT1 , located at the 8q24 oncogenic locus, has been implicated in prostate tumorigenesis and progression; however, the molecular mechanisms underlying its exon-specific transcriptional activation remains obscure. Through in silico motif discovery using FIMO analysis, we identified a high-affinity CDX1 consensus binding site within the PEAP sequence, suggesting a potential transcriptional regulatory role. DNA methylation profiling of matched prostate tumor and adjacent normal tissues from prostate cancer patients demonstrated promoter hypomethylation at PEAP, concomitant with a significant upregulation of PVT1 exon 9. While siRNA-mediated CDX1 silencing in PVT1 exon 9 overexpressing cells (MDA-PCa-2b and C22OH) attenuated PVT1 exon 9 expression, CDX1 overexpression in RWPE-1 cells enhanced PVT1 exon 9 transcription. Immunohistochemical and immunofluorescence analysis corroborated the nuclear localization and elevated expression of CDX1 in high-Gleason-grade tumors, underscoring its role as a transcriptional activator. Using digital PCR, CRISPR-mediated base editing of the CDX1 binding sequence on PEAP in MDA-PCa-2b and C22OH revealed drastic reduction in PVT1 exon 9 copy number compared to scramble. Collectively, these findings delineate a CDX1-PEAP-PVT1 signaling axis that is dependent on CDX1 binding to PEAP, thereby driving oncogenic PVT1 exon 9 overexpression. This mechanistic insight provides a novel framework for understanding PVT1 exon-specific regulation and positions the CDX1-PEAP interaction as a promising molecular target for therapeutic interventions in PVT1 exon 9 overexpressing prostate cancers.
利益披露 Disclosure
C. C. Udekwu, None.. S. K. Nuraziza, None.. S. Adams, None.. R. E. Bonnaci, None.. E. O. Olapade-Olaopa, None.. O. O. Ogunwobi, None.

← 返回 AACR 2026 检索